189 related articles for article (PubMed ID: 21274381)
1. Evaluation of Cladribine treatment in refractory celiac disease type II.
Tack GJ; Verbeek WH; Al-Toma A; Kuik DJ; Schreurs MW; Visser O; Mulder CJ
World J Gastroenterol; 2011 Jan; 17(4):506-13. PubMed ID: 21274381
[TBL] [Abstract][Full Text] [Related]
2. Cladribine therapy in refractory celiac disease with aberrant T cells.
Al-Toma A; Goerres MS; Meijer JW; von Blomberg BM; Wahab PJ; Kerckhaert JA; Mulder CJ
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1322-7; quiz 1300. PubMed ID: 16979946
[TBL] [Abstract][Full Text] [Related]
3. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy.
Tack GJ; Wondergem MJ; Al-Toma A; Verbeek WH; Schmittel A; Machado MV; Perri F; Ossenkoppele GJ; Huijgens PC; Schreurs MW; Mulder CJ; Visser OJ
Bone Marrow Transplant; 2011 Jun; 46(6):840-6. PubMed ID: 20818442
[TBL] [Abstract][Full Text] [Related]
4. Monitoring nonresponsive patients who have celiac disease.
Krauss N; Schuppan D
Gastrointest Endosc Clin N Am; 2006 Apr; 16(2):317-27. PubMed ID: 16644460
[TBL] [Abstract][Full Text] [Related]
5. Clinical staging and survival in refractory celiac disease: a single center experience.
Rubio-Tapia A; Kelly DG; Lahr BD; Dogan A; Wu TT; Murray JA
Gastroenterology; 2009 Jan; 136(1):99-107; quiz 352-3. PubMed ID: 18996383
[TBL] [Abstract][Full Text] [Related]
6. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.
Al-Toma A; Verbeek WH; Hadithi M; von Blomberg BM; Mulder CJ
Gut; 2007 Oct; 56(10):1373-8. PubMed ID: 17470479
[TBL] [Abstract][Full Text] [Related]
7. The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma).
García-Hoz C; Crespo L; Lopez N; De Andrés A; Ríos León R; Santón A; Garriga M; Butz E; León F; Roy Ariño G
Dig Dis; 2020; 38(6):490-499. PubMed ID: 32015237
[TBL] [Abstract][Full Text] [Related]
8. Treatment of clonal refractory celiac disease or cryptic intraepithelial lymphoma: A long road from bench to bedside.
Cellier C; Cerf-Bensussan N
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1320-1. PubMed ID: 17110301
[No Abstract] [Full Text] [Related]
9. Recognising and Managing Refractory Coeliac Disease: A Tertiary Centre Experience.
Nasr I; Nasr I; Beyers C; Chang F; Donnelly S; Ciclitira PJ
Nutrients; 2015 Dec; 7(12):9896-907. PubMed ID: 26633478
[TBL] [Abstract][Full Text] [Related]
10. Epidemiologic and therapeutic aspects of refractory coeliac disease - a systematic review.
Rowinski SA; Christensen E
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910801
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine and prednisone combination therapy in refractory coeliac disease.
Goerres MS; Meijer JW; Wahab PJ; Kerckhaert JA; Groenen PJ; Van Krieken JH; Mulder CJ
Aliment Pharmacol Ther; 2003 Sep; 18(5):487-94. PubMed ID: 12950421
[TBL] [Abstract][Full Text] [Related]
12. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma.
Al-Toma A; Goerres MS; Meijer JW; Peña AS; Crusius JB; Mulder CJ
Clin Gastroenterol Hepatol; 2006 Mar; 4(3):315-9. PubMed ID: 16527694
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease.
Verbeek WH; Goerres MS; von Blomberg BM; Oudejans JJ; Scholten PE; Hadithi M; Al-Toma A; Schreurs MW; Mulder CJ
Clin Immunol; 2008 Jan; 126(1):48-56. PubMed ID: 18024205
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of Enteropathy-Associated T Cell Lymphoma.
Chander U; Leeman-Neill RJ; Bhagat G
Curr Hematol Malig Rep; 2018 Aug; 13(4):308-317. PubMed ID: 29943210
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor.
Nijeboer P; van Wanrooij R; van Gils T; Wierdsma NJ; Tack GJ; Witte BI; Bontkes HJ; Visser O; Mulder C; Bouma G
United European Gastroenterol J; 2017 Mar; 5(2):208-217. PubMed ID: 28344788
[TBL] [Abstract][Full Text] [Related]
16. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease.
Hadithi M; Mallant M; Oudejans J; van Waesberghe JH; Mulder CJ; Comans EF
J Nucl Med; 2006 Oct; 47(10):1622-7. PubMed ID: 17015897
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.
Tobinai K; Uike N; Saburi Y; Chou T; Etoh T; Masuda M; Kawano F; Matsuoka M; Taguchi H; Makino T; Asano Y; Tamura K; Ohashi Y;
Int J Hematol; 2003 Jun; 77(5):512-7. PubMed ID: 12841391
[TBL] [Abstract][Full Text] [Related]
19. The MYO9B gene is a strong risk factor for developing refractory celiac disease.
Wolters VM; Verbeek WH; Zhernakova A; Onland-Moret C; Schreurs MW; Monsuur AJ; Verduijn W; Wijmenga C; Mulder CJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1399-405, 1405.e1-2. PubMed ID: 17967566
[TBL] [Abstract][Full Text] [Related]
20. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
